Filing Flows › Adma Biologics (ADMA) › Capital expenditures
Adma Biologics (ADMA) capital expenditures by quarter
Adma Biologics' capital expenditures were $2.0M in Q3 2026 (third quarter 2026), -11% from Q2 2026. Over the last 6 quarters it ranged from $1.1M (Q4 2025) to $14.4M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.0M | -11% | -86% |
| Q2 2026 | $2.3M | -11% | -7% |
| Q1 2026 | $2.5M | +135% | — |
| Q4 2025 | $1.1M | -92% | — |
| Q3 2025 | $14.4M | +493% | — |
| Q2 2025 | $2.4M | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' capital expenditures?
Adma Biologics' capital expenditures were $2.0M in Q3 2026 (third quarter 2026), -11% from Q2 2026.
How has Adma Biologics' capital expenditures changed?
Over the last 6 quarters it ranged from $1.1M (Q4 2025) to $14.4M (Q3 2025).